Pharma Archives - Page 75 of 82 - Life Sciences Times

Strand Therapeutics Promotes Prashant Nambiar to Chief Scientific Officer and Appoints Ethan Cash as Senior Vice President, Head of Portfolio Management and Program Development

November 5, 2025

Pan-Mass Challenge Donates Record $78 Million to Dana-Farber Cancer Institute

November 3, 2025

Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Expanding Clinical Data Capabilities to Accelerate Drug Development

October 29, 2025

THIS WEEK'S STORIES

BrainScope Appoints Matt Adams as Chief Executive Officer to Lead Next Phase of Growth

November 4, 2025

AVS Announces Positive Safety and Effectiveness Data from First 95 Patients in Pulse IVL IDE Study

November 5, 2025

Viridian Therapeutics Submits Biologics License Application to FDA for Veligrotug in Thyroid Eye Disease

November 3, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Pharma

Astria Therapeutics Reports Final Positive Results from All Enrolled HAE Patients in ALPHA-STAR Phase 1b/2 Trial of Navenibart

Calluna Pharma Receives U.S. FDA Orphan Drug Designation for CAL101 in Idiopathic Pulmonary Fibrosis

Delix Therapeutics Reports Positive Phase Ib Results for Zalsupindole and FDA Clearance for Phase II Trial with At-Home Administration

Corsera Health Files First Phase 1 Clinical Trial Application for Preventive RNAi Medicine Targeting Cardiovascular Disease

Zymeworks Reports Promising Early Data from Phase 1 Study of ZW191 Targeting Folate Receptor-Alpha in Advanced Solid Tumors

Most Read

Jopari Solutions Announces John Gilmartin as President to Lead Operations and Growth Strategy

Moleculent Launches Early Access Program to Support Large-Scale Study of Cell-Cell Communication

Worldwide Clinical Trials Appoints John Capicchioni as Senior Vice President, Commercial, Early Phase

Life Sciences and Investment Leaders at BioFuture 2025 Signal Renewed Optimism in Health and Biotech Sectors

EDITOR PICKS